These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 30513732)

  • 21. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Tumors.
    Fitzgerald TL; Mosquera C; Lea CS; McMullen M
    Am Surg; 2017 Jul; 83(7):799-803. PubMed ID: 28738955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
    Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
    Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute.
    Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK
    Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy].
    Holzer K
    Chirurg; 2014 Aug; 85(8):731-44. PubMed ID: 25103842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinicopathological significance of angiogenesis in hindgut neuroendocrine tumors obtained via an endoscopic procedure.
    Okubo Y; Motohashi O; Nakayama N; Nishimura K; Kasajima R; Miyagi Y; Shiozawa M; Yoshioka E; Suzuki M; Washimi K; Kawachi K; Nito M; Kameda Y; Yokose T
    Diagn Pathol; 2016 Nov; 11(1):128. PubMed ID: 27821179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathology - grading and staging of GEP-NETs.
    Capelli P; Fassan M; Scarpa A
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):705-17. PubMed ID: 23582914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nutritional Complications and the Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Laing E; Kiss N; Michael M; Krishnasamy M
    Neuroendocrinology; 2020; 110(5):430-442. PubMed ID: 31550712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression.
    Pereira SS; Pereira R; Santos AP; Costa MM; Morais T; Sampaio P; Machado B; Afonso LP; Henrique R; Monteiro MP
    Pathology; 2019 Oct; 51(6):593-599. PubMed ID: 31466863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
    Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
    Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of primary tumor resection in the management of metastatic well-differentiated neuroendocrine tumors of the small bowel and pancreas.
    Russo A; DiPeri T; Dumitra T; Tseng J; Pletcher E; Justo M; Chen C; Nissen N; Amersi F; Gong J; Hendifar A; Gangi A
    J Neuroendocrinol; 2024 Aug; 36(8):e13399. PubMed ID: 38760997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
    Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
    Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?
    Grillo F; Albertelli M; Annunziata F; Boschetti M; Caff A; Pigozzi S; Ferone D; Mastracci L
    Endocrine; 2016 Jul; 53(1):58-62. PubMed ID: 26362059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor.
    Grillo F; Albertelli M; Brisigotti MP; Borra T; Boschetti M; Fiocca R; Ferone D; Mastracci L
    Neuroendocrinology; 2016; 103(5):452-9. PubMed ID: 26337010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
    Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
    Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinicopathologic characteristics of 127 cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) studied in an oncology hospital].
    Alvarado-Cabrero I; de Anda-González J; Hernández-Hernández B; Mantilla-Morales A; Valencia-Cedillo R; Medrano-Guzmán R
    Rev Gastroenterol Mex; 2012; 77(4):174-80. PubMed ID: 23142406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
    Baumann T; Rottenburger C; Nicolas G; Wild D
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
    Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.